SUTRO BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 266.72 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2022-02-28
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was 0.00 shares.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-09-30 was 0.00 shares.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-06-30 was 0.00 shares.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 266.72K shares.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 266.72K shares, a 0.00% change from fiscal 2020.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 266.72K shares, a 0.00% change from fiscal 2019.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 266.72K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 0.00 shares derived: sum of 2 quarters · filed 2022-02-28 | 0.00 shares derived: sum of 3 quarters · filed 2022-02-28 | 266.72K shares 10-K · filed 2022-02-28 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-10 | 266.72K shares 10-Q · filed 2021-11-10 | 266.72K shares derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 266.72K shares 10-Q · filed 2021-08-09 | 266.72K shares derived: sum of 3 quarters · filed 2022-02-28 | 266.71K shares derived: sum of 4 quarters · filed 2022-02-28 | |
| 2021-03-31 | 266.72K shares 10-Q · filed 2021-05-07 | 266.72K shares derived: sum of 2 quarters · filed 2022-02-28 | 266.71K shares derived: sum of 3 quarters · filed 2022-02-28 | ||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -16.00 shares derived: sum of 2 quarters · filed 2022-02-28 | 266.72K shares 10-K · filed 2022-02-28 | ||
| 2020-09-30 | -16.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 266.72K shares 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 266.74K shares 10-Q · filed 2020-08-06 | ||||
| 2019-12-31 | 266.72K shares 10-K · filed 2021-03-18 | 266.64K shares 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |